REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

WHO recommends Eli Lilly, GSK-Vir's drugs, widening COVID-19 treatment pool

01/13/2022 | 06:01pm EDT

Jan 13 (Reuters) - A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly, and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.

WHO data shows Omicron, which is evading protection provided by many vaccines and therapies, has been identified in 149 countries. It is quickly replacing Delta as the dominant variant in several nations, forcing governments and scientists to bolster defences with testing, shots and therapies.

The panel on Thursday strongly recommended Lilly's baricitinib, sold under brand name Olumiant, for patients with severe COVID-19 in combination with corticosteroids, while conditionally endorsed GSK-Vir's antibody therapy for non-severe patients at the highest risk of hospitalization.

So far, GSK-Vir's monoclonal antibody therapy is the only one that has shown effectiveness against Omicron in lab tests, while similar treatments from Eli Lilly and Co and Regeneron Pharmaceuticals offered lower protection in such tests.

The WHO experts noted that the effectiveness of monoclonal antibody treatments -- lab-generated compounds that mimic the body's natural defences -- against new variants such as Omicron was still uncertain, and said the guidelines for this class of medicine will be updated when additional data become available.

The WHO guidelines, published in the British Medical Journal, also noted that evidence shows baricitinib improves survival rate and reduces the need for ventilation, with no observed increase in adverse effects.

French medical charity Medecins Sans Frontieres (MSF) welcomed the United Nations agency's guidelines, and said baricitinib can be a potential alternative to current WHO-recommended monoclonal antibody treatments that remain in short supply for governments and patients in many low- and middle-income countries.

MSF also said that governments must take steps to ensure that patent monopolies do not stand in the way of access to the treatment. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -2.06% 295.19 Delayed Quote.6.87%
GLAXOSMITHKLINE PLC -1.98% 1720.4 Delayed Quote.10.18%
ON SEMICONDUCTOR CORPORATION -4.56% 55.83 Delayed Quote.-17.80%
REGENERON PHARMACEUTICALS, INC. -1.25% 659.2 Delayed Quote.4.38%
VIR BIOTECHNOLOGY, INC. -1.65% 22.71 Delayed Quote.-45.76%
All news about REGENERON PHARMACEUTICALS, INC.
05/17Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
PR
05/16Regeneron Pharmaceuticals, Inc. - HIGH SCHOOL SCIENTISTS FROM AROUND THE WORLD WIN NEAR..
AQ
05/13High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at ..
PR
05/13High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at ..
PR
05/10TRANSCRIPT : Regeneron Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C..
CI
05/05RBC Capital Adjusts Regeneron Pharmaceuticals Price Target to $658 From $647, Maintains..
MT
05/04Regeneron's COVID drug sales outside U.S. help revenue beat
RE
05/04GLOBAL MARKETS LIVE : Airbnb, Pandora, Apple, Twitter, Meta...
05/04WALL STREET STOCK EXCHANGE : Finally, it's time for Powell's speech
05/04TRANSCRIPT : Regeneron Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 844 M - -
Net income 2022 4 040 M - -
Net cash 2022 8 670 M - -
P/E ratio 2022 17,8x
Yield 2022 -
Capitalization 71 026 M 71 026 M -
EV / Sales 2022 5,26x
EV / Sales 2023 4,77x
Nbr of Employees 10 492
Free-Float 81,0%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 659,20 $
Average target price 689,35 $
Spread / Average Target 4,57%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.4.38%71 026
GILEAD SCIENCES, INC.-12.93%79 298
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-18.77%41 409
BIONTECH SE-39.08%38 169
GENMAB A/S-19.16%19 651